Medical research rarely stands still, and two recent studies are a reminder of just how quickly the landscape can shift.

‍Reprogramming Immunity

Engineered to target blood cancers, CAR T-cell therapy is now being tested across a broad spectrum of autoimmune diseases including multiple sclerosis, lupus and stiff person syndrome. The treatment works by extracting a patient's own T cells and reprogramming them to hunt and eliminate the rogue B cells driving autoimmune attacks, essentially resetting the immune system.

Early clinical results are striking, with patients showing meaningful improvement in mobility and daily life. Challenges remain, including a steep price tag, infection vulnerability during recovery, and uncertain long-term side effects. Next-generation versions using mRNA rather than DNA aim to reduce those risks and lower costs. Read more

 Liver's Surprising Role in Alzheimer's

A study published in the journal Neuron offers an unexpected new pathway for treating Alzheimer's disease. Rather than attempting to penetrate the difficult blood-brain barrier, researchers delivered a protective gene variant to the liver of mice with Alzheimer's markers. The liver then cleared amyloid protein from the bloodstream, and because the brain and blood maintain an amyloid balance, plaques in the brain diminished as well. Treated mice showed less brain inflammation and improved performance on memory tests. Human trials are not yet underway, but the approach is drawing serious attention. Read more

‍